Johns Hopkins Wilmer Eye Institute’s MACULA 2021

Over the past several years, there is a growing body of medical evidence demonstrating a clear biologic rationale for targeting vascular endothelial growth factors in the treatment of the neovascular form of agerelated macular degeneration, diabetic retinopathy, and related diseases. Furthermore, there are new imaging and therapeutic approaches to vitreomacular interface abnormalities, intraocular tumors, posterior uveitis, hereditary retinal degenerations, as well as surgical diseases of the retina. These areas of investigation are relatively new, and most ophthalmologists are not aware of the myriad of new clinical trials relevant to these diseases.
Thus, these subjects are areas of great interest both to ophthalmologists who treat these diseases and to those who refer these cases for further management. Presentations were chosen to emphasize new information and consensus on the use of these biologic agents to treat the neovascular and non-neovascular forms of age-related macular degeneration, vitreomacular interface abnormalities, diabetic retinopathy, intraocular tumors, and posterior uveitis. In addition, cases were chosen highlighting new information being reported by randomized clinical trials in these disease areas.
WHO SHOULD ATTEND
This activity is intended for ophthalmologists, optometrists, and ophthalmic allied health professionals.
OBJECTIVES
After attending this activity, the learner will demonstrate the ability to:

Recognize the role of anti-angiogenic treatments for eyes with choroidal neovascularization from age-related macular degeneration or diabeticretinopathy, including proliferative diabetic retinopathy and diabetic macular edema.
Evaluate recent clinical studies evaluating treatments for hereditary retinal degenerations.
Recognize the role of imaging in the management of vitreomacular interface abnormalities.
Review the current and emerging therapeutic approaches for surgical retinal diseases.
Summarize the evidence of surgical and medical treatments for intraocular tumors.
Detect which patients are appropriate for biologic treatments of posterior uveitis.

The Johns Hopkins Wilmer Eye Institute’s MACULA 2021 conference was best for ophthalmologists, retina specialists, fellows, residents, and vision researchers who wanted to deepen their expertise in macular diseases and learn how to apply the latest evidence-based therapies in clinical practice.
Who Should Attend

Retina specialists and ophthalmologists managing patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion
Residents and fellows in ophthalmology seeking case-based learning and exposure to cutting-edge treatments
Vision scientists and researchers interested in translational applications of anti-VEGF and emerging biologics
Allied eye care professionals supporting retinal disease management in clinical settings

What You’d Learn
The 2021 program emphasized advances in macular disease therapies and practical strategies for integrating them into patient care. Key highlights included:

Evidence supporting vascular endothelial growth factor (VEGF) inhibition in neovascular AMD, diabetic retinopathy, and related diseases
Case-based discussions showing how clinical trial data translates into real-world practice
Updates on diagnostic imaging technologies for macular disease
Networking opportunities with Johns Hopkins faculty and international retina experts

 
+ Topics:
Saturday, January 23, 2021

7:30AM – 7:55AM Sign into Zoom and Opportunity to Visit Virtual Exhibit Hall
7:55AM – 8:00AM Welcome and Conference Goals J. Fernando Arevalo, MD, PhD Neil Bressler, MD
8:00AM – 8:15AM Recent Classification Recommendations in AMD K. Bailey Freund, MD
8:15AM – 8:30AM Clinical Trials for Geographic Atrophy Carl D Regillo, MD
8:30AM – 8:45AM Brolucizumab-Related Vasculitis in Clinical Trials and Practice Jeffrey S Heier, MD
8:45AM – 9:00AM Where Does Faricimab Fit Into Management of Neovascular AMD John A Wells III, MD
9:00AM – 9:15AM Phase 3 Trials from Port Delivery Systems for Neovascular AMD Carl Awh, MD
9:15AM – 9:30AM Role of Genetics and Metabolomics in AMD Deeba Husain, MD
9:30AM – 10:00AM How Would You Manage These Macular Degeneration Cases In 2021? Susan Bressler, MD Adrienne Scott, MD David Baranano, MD, PhD Jason Hsu, MD
10:30AM – 10:45AM State of Gene Therapy Rachel Huckfeldt, MD, PhD
10:45AM – 11:00AM Regenerative Medicine for Hereditary Retinal Degenerations Mandeep Singh, MD, PhD
11:00AM – 11:15AM Home Monitoring Michael Elman, MD
11:15AM – 11:30AM OCT Angiography: Current Status Nadia Waheed, MD, MPH
11:30AM – 12:00PM How Would You Manage These Vitreoretinal Surgery Cases in 2021? Cindy X Cai, MD Mira Sachdeva, MD, PhD David M Wu, MD, PhD John B Miller, MD Yoshihiro Yonekawa, MD
1:00PM – 1:30PM How Would You Manage These Ocular Oncology Cases in 2021? Mary Beth Aronow, MD Zelia M Correa, MD, PhD Jasmine Francis, MD J William Harbour, MD Ivana Kim, MD
1:30PM – 1:45PM Treatment Regimens for DME in 2021 Jennifer Sun, MD, MPH
1:45PM – 2:00PM Proliferative Diabetic Retinopathy – PRP or Anti-VEGF or Both? Jeffrey G Gross, MD
2:00PM – 2:15PM Role of Wide-Field Imaging in Diabetic Retinopathy Lloyd Aiello, MD
2:15PM – 2:30PM Vitreous Hemorrhage from PDR: Vitrectomy or Anti-VEGF Andrew Antoszyk, MD
2:30PM – 3:00PM How Would You Manage These Diabetic Retinopathy Cases in 2021? Mark Breazzano, MD Adam S Wenick, MD, PhD Sunir Garg, MD Benjamin J. Kim, MD
3:30PM – 3:45PM Treatment Advances for Uveitis in 2021 Douglas A Jabs, MD, MBA
3:45PM – 4:00PM Deeper Understanding of Mac Tel 2 Pathophysiology Richard Spaide, MD
4:00PM – 4:15PM Genetic and Other Approaches to Sustained Drug Delivery Peter A Campochiaro, MD
4:15PM – 4:30PM Potential Role of Aqueous Biomarkers with Intravitreal Injections Akrit Sodhi, MD, PhD
4:30PM – 4:45PM Artificial Intelligence and Retina in 2021 T. Y. Alvin Liu, MD
4:45PM – 5:00PM Advances in Pediatric Retina in 2021 Cynthia Toth, MD
5:00PM – 5:05PM Closing Summary John Thompson, MD